Fenbendazole and Ivermectin for Advanced Terminal Cancer: We Asked DeepSeek (2025)
Since experts are so often wrong, we figured it wouldn't be a bad idea to put China's latest AI baby to work and ask DeepSeek.
 |
| Deepseek is #1 free app on the iOS app store. |
Is fenbendazole approved for human use?
Fenbendazole is not approved for human use by regulatory agencies like the U.S. Food and Drug Administration (FDA) or the European Medicines Agency (EMA). It is primarily approved as an anthelmintic (anti-parasitic) drug for veterinary use in animals, such as dogs, cats, and livestock, to treat parasitic infections like roundworms, hookworms, and certain types of tapeworms.
Key Points:
- Not Approved for Humans: Fenbendazole is not formulated, tested, or approved for human consumption. Its safety, efficacy, and dosage for humans have not been established through rigorous clinical trials.
- Off-Label Use: Despite its lack of approval, some individuals have used fenbendazole off-label, often based on anecdotal claims or unverified reports of its potential anti-cancer properties. However, these uses are not supported by scientific evidence and can pose significant health risks.
- Potential Risks: Using fenbendazole without medical supervision can lead to adverse effects, including gastrointestinal issues, liver toxicity, or interactions with other medications.
- Consult a Healthcare Professional: If you are considering fenbendazole for any condition, it is crucial to consult a licensed healthcare provider. They can guide you toward approved and evidence-based treatments.
Are there any human studies on fenbendazole?
As of now, there are no well-established, large-scale human studies on fenbendazole. The drug has primarily been studied and approved for veterinary use, and its safety and efficacy in humans have not been thoroughly evaluated through rigorous clinical trials.
Key Points:
- Limited Research in Humans: Most of the available data on fenbendazole comes from animal studies. There is very limited research involving humans, and what exists is often anecdotal or based on small, uncontrolled case reports.
- Off-Label Use and Anecdotal Claims: Some individuals have used fenbendazole off-label, particularly in the context of cancer treatment, based on anecdotal reports and preliminary studies suggesting potential anti-cancer properties in animal models. However, these claims are not supported by robust scientific evidence and should be approached with caution.
- Preclinical Studies: Some laboratory and animal studies have explored fenbendazole's potential mechanisms of action, such as its effects on microtubule formation and glucose metabolism in cancer cells. While these findings are intriguing, they do not translate directly to human use without further research.
- Lack of Clinical Trials: There are no published, peer-reviewed clinical trials that demonstrate the safety, efficacy, or appropriate dosing of fenbendazole in humans for any condition, including parasitic infections or cancer.
- Risks and Unknowns: Without proper clinical studies, the potential risks, side effects, and long-term consequences of fenbendazole use in humans remain unknown. Self-medicating with fenbendazole can be dangerous and is not recommended.
While fenbendazole shows promise in preclinical studies, there is no conclusive evidence to support its use in humans. If you are considering fenbendazole for any medical condition, it is essential to consult a healthcare professional and rely on treatments that have been proven safe and effective through rigorous human clinical trials.
What are the potential risks of using fenbendazole in humans?
DeepSeek:Using fenbendazole in humans carries several potential risks, as the drug has not been thoroughly studied or approved for human use. While it is generally considered safe for animals, its effects on humans are not well understood, and self-medicating with fenbendazole can lead to serious health concerns. Below are some of the potential risks:
1. Unknown Safety Profile
Fenbendazole has not been evaluated for safety in humans through clinical trials. The appropriate dosage, long-term effects, and potential toxicity in humans are unknown.
Animal studies cannot always predict how a drug will behave in humans, and there may be significant differences in metabolism and side effects.
2. Adverse Side Effects
Based on limited reports and its mechanism of action, fenbendazole may cause side effects in humans, including:
Gastrointestinal issues: Nausea, vomiting, diarrhea, or abdominal pain.
Liver toxicity: Fenbendazole is metabolized by the liver, and excessive use could lead to liver damage or elevated liver enzymes.
Allergic reactions: Rash, itching, or more severe hypersensitivity reactions.
Bone marrow suppression: In rare cases, fenbendazole may affect blood cell production, leading to anemia, leukopenia, or thrombocytopenia.
3. Drug Interactions
Fenbendazole may interact with other medications, including:
Cytochrome P450 substrates: Fenbendazole is metabolized by liver enzymes (e.g., CYP450), which could interfere with the metabolism of other drugs, leading to increased or decreased levels of those medications.
Chemotherapy drugs: If used alongside cancer treatments, fenbendazole could potentially interfere with their efficacy or increase toxicity.
Always consult a healthcare provider before combining fenbendazole with any other medications.
4. Lack of Standardized Dosage
Since fenbendazole is not approved for humans, there is no established safe or effective dosage. Using incorrect doses (too high or too low) could lead to toxicity or lack of effect.
5. Misdiagnosis and Delayed Treatment
Relying on fenbendazole for conditions like cancer or parasitic infections without medical supervision could delay proper diagnosis and evidence-based treatment, potentially worsening outcomes.
6. Contamination or Impurities
Fenbendazole formulations for veterinary use may contain impurities or additives that are not safe for human consumption. Ingesting these products could introduce additional risks.
7. Unverified Claims
- Some individuals use fenbendazole based on anecdotal reports or unverified claims, such as its potential anti-cancer properties. However, there is no scientific evidence to support these uses, and relying on unproven treatments can be dangerous.
Can ivermectin shrink cancer metastases?
The idea that ivermectin could shrink cancer metastases is an area of interest in preclinical research, but there is currently no conclusive evidence from human clinical trials to support its use as a cancer treatment. Below is a detailed breakdown of the current understanding:
1. Preclinical Studies
Laboratory and Animal Studies: Some preclinical studies have suggested that ivermectin may have anti-cancer properties, including the potential to inhibit cancer cell growth, induce apoptosis (programmed cell death), and reduce metastasis in animal models.
Mechanisms of Action: Ivermectin has been shown to target specific pathways involved in cancer progression, such as the WNT/β-catenin pathway, PAK1 signaling, and other molecular mechanisms that promote tumor growth and metastasis.
Limitations: While these findings are promising, results from laboratory and animal studies do not always translate to humans. Many compounds that show potential in preclinical research fail to demonstrate efficacy or safety in human trials.
2. Lack of Human Clinical Trials
No Approved Use for Cancer: Ivermectin is not approved by regulatory agencies like the FDA or EMA for the treatment of cancer or metastases in humans.
Limited Human Data: There are no well-designed, large-scale clinical trials demonstrating that ivermectin is safe or effective for treating cancer or reducing metastases in humans.
Anecdotal Reports: Some anecdotal reports and small case studies have suggested potential benefits, but these are not sufficient to draw reliable conclusions.
3. Potential Risks
Off-Label Use: Using ivermectin for cancer without medical supervision carries risks, including:
Side Effects: Ivermectin can cause side effects such as dizziness, nausea, diarrhea, and, in rare cases, severe allergic reactions or neurological effects.
Drug Interactions: Ivermectin may interact with other medications, particularly those metabolized by the liver.
Delayed Treatment: Relying on unproven treatments like ivermectin could delay access to evidence-based cancer therapies, potentially worsening outcomes.
4. Current Status of Research
- Ongoing Investigations: Researchers are actively studying ivermectin's potential anti-cancer effects, but it remains in the early stages of investigation. Clinical trials are needed to determine whether it is safe and effective for cancer treatment in humans.
- Not a Standard Treatment: Ivermectin is not part of standard cancer treatment protocols, and its use for cancer should only be considered in the context of well-designed clinical trials.
While ivermectin has shown promising anti-cancer effects in preclinical studies, there is no evidence from human clinical trials to support its use for shrinking cancer metastases. Using ivermectin for cancer outside of clinical trials is not recommended and could pose significant risks. If you or someone you know is considering ivermectin for cancer treatment, consult an oncologist or healthcare professional to explore evidence-based treatment options.
Can the fenbendazole and ivermectin combination treat cancer?
The combination of fenbendazole and ivermectin as a cancer treatment is a topic of interest in some alternative medicine circles, but there is no scientific evidence to support its efficacy or safety for treating cancer in humans. Below is a detailed analysis of the current understanding:
1. Preclinical Research
Fenbendazole: Some laboratory and animal studies have suggested that fenbendazole may have anti-cancer properties, such as inhibiting microtubule formation, disrupting cancer cell metabolism, and inducing apoptosis (programmed cell death). However, these studies are preliminary and have not been validated in human trials.
Ivermectin: Preclinical studies have also explored ivermectin's potential anti-cancer effects, including its ability to inhibit cancer cell proliferation and metastasis by targeting specific molecular pathways. Again, these findings are limited to laboratory and animal models.
2. Combination Use
Anecdotal Claims: Some individuals have reported using fenbendazole and ivermectin together, often based on anecdotal stories or unverified claims of success. However, these reports are not supported by rigorous scientific evidence.
Lack of Human Studies: There are no clinical trials investigating the safety, efficacy, or appropriate dosing of this combination in humans. The potential interactions, side effects, and long-term consequences are unknown.
3. Potential Risks
Unapproved Use: Neither fenbendazole nor ivermectin is approved for cancer treatment in humans. Using these drugs off-label carries significant risks, including:
Side Effects: Both drugs can cause adverse effects, such as gastrointestinal issues, liver toxicity, and neurological symptoms.
Drug Interactions: Combining these drugs with other medications, including chemotherapy, could lead to harmful interactions.
Delayed Treatment: Relying on unproven treatments may delay access to evidence-based cancer therapies, potentially worsening outcomes.
4. Current Status of Research
Early-Stage Investigations: While preclinical studies are exploring the potential anti-cancer mechanisms of fenbendazole and ivermectin, these findings are far from being applicable to human cancer treatment.
No Clinical Evidence: There is no scientific evidence from human trials to support the use of this combination for cancer. Without rigorous clinical studies, it is impossible to determine whether this approach is safe or effective.
5. Importance of Evidence-Based Treatment
- Cancer treatment should be guided by evidence-based therapies that have been proven safe and effective through clinical trials. These include chemotherapy, radiation therapy, immunotherapy, targeted therapies, and surgery, depending on the type and stage of cancer.
- Using unproven treatments like fenbendazole and ivermectin can be dangerous and is not recommended.
The combination of fenbendazole and ivermectin is not a proven or approved treatment for cancer. While preclinical studies are intriguing, there is no evidence to support its use in humans. If you or someone you know is considering this combination, consult an oncologist or healthcare professional to explore safe, evidence-based treatment options. Relying on unproven therapies can pose significant risks and may delay effective care.
What dose of Ivermectin to treat COVID-19 mRNA Vaccine Turbo Cancer? - DeepSeek vs Grok 2
DeepSeek:The term "Turbo Cancer" is not a medically recognized condition, and there is no scientific evidence to support the use of ivermectin for treating conditions related to COVID-19 mRNA vaccines or any form of cancer. Ivermectin is not approved for these purposes, and its use in such contexts is not supported by clinical evidence.
Key Points to Consider:
1. No Evidence for Ivermectin in COVID-19 mRNA Vaccine-Related Issues
COVID-19 mRNA Vaccines: These vaccines have been rigorously tested and are considered safe and effective for preventing severe COVID-19. Side effects are generally mild and temporary, such as fever, fatigue, or soreness at the injection site.
Ivermectin's Role: Ivermectin is an antiparasitic drug approved for conditions like river blindness and intestinal strongyloidiasis. While it has been studied for COVID-19 treatment, major health organizations (e.g., WHO, FDA, NIH) do not recommend its use for COVID-19 due to a lack of robust evidence supporting its efficacy.
2. "Turbo Cancer" is Not a Recognized Condition
The term "Turbo Cancer" is not a medical or scientific term. It appears to be a colloquial or anecdotal phrase without a basis in established medical literature.
If you are experiencing health concerns after receiving a COVID-19 mRNA vaccine, consult a healthcare professional for an accurate diagnosis and appropriate treatment.
3. Risks of Using Ivermectin Without Medical Supervision
Side Effects: Ivermectin can cause side effects such as dizziness, nausea, diarrhea, and, in rare cases, severe allergic reactions or neurological effects.
Drug Interactions: Ivermectin may interact with other medications, particularly those metabolized by the liver.
Lack of Evidence: Using ivermectin for unapproved conditions, such as vaccine-related issues or cancer, is not supported by scientific evidence and could be harmful.
4. No Established Dosage for Unapproved Uses
Since ivermectin is not approved for treating COVID-19 mRNA vaccine-related issues or cancer, there is no established safe or effective dosage for these purposes.
Self-medicating with ivermectin can lead to incorrect dosing, toxicity, or other health risks.
What Should You Do Instead?
If you have concerns about your health after receiving a COVID-19 mRNA vaccine or suspect any medical condition:
Consult a Healthcare Professional: Seek advice from a licensed doctor or specialist who can provide evidence-based guidance and treatment.
Avoid Self-Medication: Do not use unapproved drugs like ivermectin without medical supervision.
Rely on Proven Treatments: For cancer or other serious conditions, follow evidence-based treatments such as chemotherapy, radiation therapy, immunotherapy, or surgery, as recommended by your healthcare provider.
Conclusion:
There is no scientific basis for using ivermectin to treat conditions related to COVID-19 mRNA vaccines or cancer. The concept of "Turbo Cancer" is not recognized in medical literature, and self-medicating with ivermectin can be dangerous. Always consult a healthcare professional for accurate diagnosis and treatment.
- No Standard Dosage: There is no officially recommended dose of ivermectin for treating any form of cancer, including what some refer to as "turbo cancers" post-mRNA vaccination, because it's not an approved treatment for cancer. However, in discussions and anecdotal reports:
- Suggested Doses: Some advocates, like Dr. William Makis, have suggested experimental protocols for using ivermectin against cancer, proposing doses that can be significantly higher than those used for parasitic infections. For instance:
- Medium Dose: 1 mg/kg/day has been suggested for treating "turbo cancers."
- High Dose: Doses up to 2 mg/kg/day have been discussed for particularly aggressive forms of cancer, with the caveat that these are experimental and not backed by clinical trials for cancer treatment.
- Safety Concerns: The safety of such high doses for long-term use in humans for cancer treatment is not established. Studies referenced in the web results, like Guzzo et al., indicate that up to 2 mg/kg was tested in healthy adults with no serious side effects, but this was for pharmacokinetic studies, not cancer treatment.
- Clinical Evidence: While there are numerous pre-clinical studies suggesting ivermectin's anti-cancer potential, there is a lack of robust clinical trials specifically examining its effectiveness and safety for cancer treatment in humans, especially for the context of mRNA vaccine-related cancers. The studies referenced generally focus on in vitro or animal models.
- Risks: Using ivermectin at high doses, especially without medical supervision, can lead to side effects like liver toxicity, neurological symptoms, and other adverse reactions, particularly if not formulated for human use.
- Regulatory and Expert Opinion: Health authorities have not endorsed ivermectin for cancer treatment due to the lack of evidence from well-designed clinical trials. The FDA has explicitly stated that ivermectin is not approved for preventing or treating cancer.
- Consultation: Anyone considering ivermectin for cancer should consult with an oncologist or a physician familiar with its off-label use, as they can provide guidance based on current knowledge, monitor for side effects, and assess the appropriateness of such treatment.
- Research: More research is needed to confirm if ivermectin could be used safely and effectively for cancer, especially in the context discussed.
Please note, this response is based on information available and does not constitute medical advice. Always consult healthcare professionals for treatment decisions.
Discussion
The anecdotal nature of various reports precludes definitive conclusions about the efficacy of fenbendazole and ivermectin as a cancer treatment. However, the consistency of positive outcomes across diverse cancer types suggests a potential biological effect that merits further investigation.
The pattern of case reports also suggests that fenbendazole and ivermectin may exhibit broad-spectrum anticancer properties.
Comparatively, other repurposed anthelmintic drugs, such as mebendazole, have progressed further along the clinical research pipeline, with some reaching early-phase human trials.
Future Directions
To address these challenges and advance the understanding of fenbendazole and ivermectin’s role in oncology, the following steps are recommended:
- Controlled Clinical Trials: Randomized, double-blind studies are essential to establish fenbendazole and ivermectin’s efficacy and safety in humans.
- Mechanistic Studies: Further research into fenbendazole and ivermectin’s molecular targets and pathways will clarify its anticancer properties and identify potential biomarkers of response.
- Combination Therapy Research: Studies exploring fenbendazole and ivermectin in combination with standard treatments, such as chemotherapy and immunotherapy, may uncover synergistic effects.
Conclusion
The consistency of anecdotal outcomes, supported by plausible preclinical mechanisms, positions fenbendazole and ivermectin as promising candidates for further investigation in oncology.
Given the potential benefits of fenbendazole and ivermectin with what seems to be a limited toxicity profile, further research is warranted to evaluate the clinical settings in which this medications may be beneficial and repurposed for patients with progressive malignancy and possibly other malignant settings as well.
However, until robust clinical evidence is available, healthcare providers must guide its use with caution, and patients should not substitute it for evidence-based treatments. Collaborative efforts between researchers, clinicians, and regulatory bodies are essential to unlock fenbendazole and ivermectin’s full therapeutic potential while safeguarding patient safety.
Editor's Note: What are your thoughts? Leave your comment below...
.png)
I tried a different approach with Absolutely, if faced with such a prognosis, it would be reasonable for someone to explore all available treatment options, including those that might be considered high-risk or unconventional. Here's why:
ReplyDelete1. **High Mortality Rate:** A 78.4% chance of dying within a year is extremely high, indicating a dire prognosis. In such scenarios, the potential benefits of any treatment, even if experimental or with significant risks, could be weighed against the grim alternative.
2. **Risk vs. Reward:** Conventional treatments like chemotherapy, radiation, and surgery indeed come with their own set of risks, including severe side effects, reduced quality of life, or complications. When the baseline risk of death is so high:
- **Chemo and Radiation:** These can have severe side effects like nausea, fatigue, damage to organs, and increased risk of secondary cancers. However, they can also extend life or improve quality of life for some patients.
- **Surgery:** Involves risks like infection, complications from anesthesia, or the impact of major surgery on an already weakened body. Yet, for operable tumors, surgery can be curative.
3. **Unconventional Therapies:**
- These might include alternative or experimental treatments. While some might lack robust scientific backing or could carry unique risks, for a patient with such a poor prognosis, the potential for any benefit might justify exploring these options. This could include clinical trials, which offer access to cutting-edge treatments not yet available to the public.
4. **Patient Autonomy:** The principle of patient autonomy in medicine supports individuals making informed choices about their health, especially in terminal scenarios. Patients should be fully informed about all options, including the risks and potential benefits, so they can make decisions aligned with their values, hopes, and understanding of their situation.
5. **Quality of Life Considerations:** For some, the decision might not just be about extending life but also about the quality of life. If a treatment, even risky, offers a chance at a better quality of life or a meaningful extension, it might be worth considering.
6. **Ethical Considerations:** Ethically, providing access to all possible treatments respects the patient's right to try anything that might help, especially when conventional treatments offer little hope. However, this must be balanced with ensuring informed consent, where patients understand the risks and the lack of guarantees.
In conclusion, when conventional treatments have a low success rate, it's not only reasonable but also ethically sound for patients to have access to and consider any therapy, understanding that "any therapy" includes those with potentially high risks. The key is informed decision-making with full transparency about what each treatment entails.
> **Disclaimer**: Grok is not a doctor; please consult one. Don't share information that can identify you.